# 1. Financial Performance ## A. Key Figures * Revenue Growth: 22.5% YoY (Q2) and 14.5% (H1 FY26) * EBITDA: ₹48 Cr (Q2) · ₹93 Cr (H1) | Margin: 8.4% (Q2) · about 8% (H1) * **Unit Volume Growth:** **16.7%** (Q2) ## B. Revenue Recognition & Financial Impact * **Revenue Reclassification:** Flipkart’s new settlement process reduced reported revenue by **₹28 Cr** due to direct deduction of logistics/fulfilment costs, with **no impact on net profitability or cash flow**. * **Like-for-Like Reporting:** Company will continue to provide adjusted financials for comparability, ensuring transparency on underlying performance trends. ## C. Profitability Drivers & Outlook * **Sustained Margin Resilience:** Underlying EBITDA and PAT unaffected by revenue reclassification; **gross margin remains above 71%**, supported by **scale-driven procurement**, **favorable mix** (face skincare, prestige brands), and **marketing efficiencies**. * **Operating Leverage Building:** Scaling operations driving improved return on marketing spend, particularly in maturing brands, enabling **targeted annual operating margin expansion of 50–100 bps**. * **Confident Margin Guidance:** Management expects to sustain **EBITDA margins at or above the current 7% range** in coming quarters, underpinned by H1 strength. --- # 2. Volume & Pricing Trends ## A. Key Figures * **Like-to-Like Revenue:** **₹440 Cr** → **₹538 Cr** (Q2 FY26, +4% YoY) * **Core Category Contribution:** **70%** → **75%** (target: **84–85%** in 4–6 quarters) ## B. Like-to-Like Growth * **Stable Underlying Growth:** Like-to-like revenue growth remains consistent at **5%**, reflecting sustained demand and effective core brand execution. * **Outperformance in Strategic Segments:** High double-digit growth in Mamaearth and younger brands, with **select categories exceeding 20% growth** across all trade channels. * **Strategic Focus Driving Results:** Growth fueled by simplification strategy—prioritizing core categories and concentrating investment for scale and share gains. ## C. Core Category Pricing * **Portfolio Rationalization Accelerating:** Increased core category contribution underscores successful shift toward high-potential segments, supporting pricing power and margin resilience. --- # 3. Channel & Distribution ## A. Key Figures * **Direct Outlet Billings:** **35% YoY growth** (sequential improvement in secondary sales) · **80% of current billing** from direct distribution * **Retail Outlet Reach:** **250,000+ outlets** (Nielsen data) * **Distribution Mix Shift:** Direct distributor contribution up to **80%** (from one-third) · Super-stockist share down to **20%** (from two-thirds) * **Quick Commerce Revenue Contribution:** **10% of revenues**, fastest-growing channel * **Offline Business Run Rate:** **INR 100 Cr+ annualized** ## B. Direct Distribution * **Structural Upgrade Achieved:** Successful shift to a two-layered, direct-led model in top 100 cities, establishing a leaner and more controlled distribution foundation. * **High Penetration, Near-Complete Rollout:** Direct distribution now covers **85% of targeted clusters**, with full rollout expected in **3–6 months**. * **Execution Gains from Project Neev:** Strong double-digit growth in secondary sales and billing share driven by improved offline execution and brand pull. ## C. Quick Commerce * **Strategic Channel Acceleration:** Quick commerce is the fastest-growing channel with **healthy economics**, now representing a double-digit revenue share. * **Expanding Addressable Market:** Unlocking growth in sub-₹100 to sub-₹200 price bands—historically low-penetration segments—via speed and convenience. * **Portfolio Synergy Potential:** High-repeat, low-price categories show strongest traction, indicating scalable repeat-purchase dynamics. ## D. Offline Expansion * **Offline Scale Validated:** Business now exceeds **INR 100 Cr annual run rate**, supporting continued investment in physical market presence. --- # 4. Brand & Product Performance ## A. Key Figures * **Young Brands Growth:** **20%** YoY growth * **Derma Co Net Sales ARR:** **₹750 Cr** (quarterly) * **Derma Co EBITDA Margin:** **High single-digit** % * Mamaearth Tree Plantation: 1 million trees achieved (2025 target met) · 1 million new target (5-year) ## B. Mamaearth Growth * **Return to Growth:** Mamaearth has re-entered positive territory across primary and secondary sales, with **strong double-digit momentum** in key channels and market share gains. * **Core Category Focus:** Growth will be driven by **6 core categories**, while non-core segments decline; body care identified as next potential growth pillar. * **Product Milestone:** Rice face wash joins **₹100 Cr+ club**, becoming the third face wash SKU to reach this scale, reflecting strong consumer resonance. * **Growth Trajectory:** Outlook calls for **high single-digit growth** in the near term, accelerating to **double-digit expansion by Q4**, supported by base normalization and organic recovery. * **Premiumization & Trust:** Collaborations with experts (e.g., Dr. Sarins) and **blind testing validation** reinforce product superiority and premium brand positioning. ## C. Young Brands * **Robust Portfolio Momentum:** Young brands delivered **strong 20% YoY growth**, led by innovation and playbook execution at BBlunt, Aqualogica, Dr. Sheth’s, Staze, and Derma Co. * **Derma Co Leadership:** Emerged as **India’s #1 sunscreen brand (2024)** with significant headroom in core categories; expanding into **moisturizers and hair care** (each ~₹10,000 Cr opportunity). * **Staze & Innovation:** Coloured beauty brand Staze achieving **triple-digit YoY growth** with strong PMF; Aqualogica launched **first in vivo tested anti-pollution sunscreen**, addressing unmet Indian consumer needs. * **Strategic Brand Building:** New brands launched only for clear white spaces (e.g., Lumineve for night care); **Brand Factory** drives 0-to-1 scaling, complemented by M&A and partnerships like **Fang (minority stake)**. * **Capital-Efficient Model:** Organic brand creation viewed as **strategic differentiator** vs. acquisition-heavy peers, offering long-term capital efficiency and control. ## D. Prestige Portfolio * **Prestige Expansion:** Portfolio now includes **Lumineve, Dr. Sheth’s, and Derma Co**, with Lumineve priced **~5x** mainstream offerings and exclusive Nykaa distribution to maintain premium positioning. * **First-to-World & First-to-India:** Lumineve is **first dedicated night care brand** globally; Dr. Sheth’s introducing **PDRN, Argireline**—new actives to India—to strengthen scientific credibility. * **Long-Term Platform Play:** Lumineve in **build phase with no near-term revenue targets**, focused on foundation-building for potential global scalability. * **Oral Beauty Vision:** Fang backed as **future prestige oral care leader**, aligning with three-stage evolution from hygiene to aesthetic expression. --- # 5. Input Cost & Supply Risks ## A. China Supply Chain * **Headline:** Increasing confidence in managing China-based packaging and conversion supply chain, supporting consistent brand growth. ## B. Shade Complexity * **Headline:** Coloured beauty remains a learning-intensive category due to **shade-based supply chain complexities**, requiring ongoing adaptation. --- # 6. Guidance & Outlook ## A. Key Figures * **Revenue Milestone Target:** **INR1,500 Cr** and **INR2,000 Cr** for Mamaearth (path to category expansion) * **Derma Co Revenue Goal:** **INR1,000 Cr+** brand target within 1–2 years * **Oral Beauty Market Opportunity:** **$700 Mn** by 2030 (India) * **Prestige Skincare Market Potential:** **$4 Bn** opportunity in India over next decade ## B. Revenue Milestones * **Growth Trajectory:** Mamaearth positioned for sustained **double-digit growth**, with future category expansion contingent on hitting key profitability and revenue thresholds. ## C. Category Expansion * **Oral Beauty as Next Frontier:** Strategic focus on emerging **oral beauty** segment, backed by $700 Mn market potential and global analogs showing successful disruption post-skin care cycle. * **Derma Co Scaling Aggressively:** Expansion into moisturizers and shampoos supports near-term goal of building a **INR1,000 Cr+** brand within 1–2 years. * **Wellness & Regimen Trends Under Evaluation:** Company actively assessing entry into **wellness and nutraceuticals** via brand extensions or new initiatives, with formal strategy pending further hypothesis building. * **Long-Term Category Vision:** Management sees **$4 Bn prestige skincare** and broader **innovation-led brand creation** as defining opportunities for Indian beauty over the next decade.